Mounjaro KwikPen “Click Counting”: The Arithmetic, the Limits and the Safety Conversation
In this article & details
Bottom line: “Click counting” charts for Mounjaro (tirzepatide) KwikPen are circulating as a way to obtain a lower dose from a higher-strength pen. The arithmetic behind many of these charts is internally consistent, but the method is off-label. Lilly’s Canadian instructions describe the KwikPen as a device that delivers four fixed 0.6 mL doses and direct the user to dial until “1” appears in the dose window—not to select a partial dose by counting clicks.
This article explains the calculations found in online handouts. It is not an individualized dosing instruction, does not endorse click counting, and should not replace the Canadian product monograph, the prescriber’s directions or hands-on device training.
Why pharmacists are being asked about clicks
Cost, supply and gradual titration have led some patients and clinicians to discuss using a higher-strength pen for a smaller dose. Two Canadian clinic handouts reviewed for this article openly describe the practice as off-label. They also acknowledge risks such as dosing error, contamination and use beyond the manufacturer-supported in-use period.
The current Canadian product monograph lists six KwikPen strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.6 mL dose. Each pen contains four fixed weekly doses. Lilly’s separate Canadian Instructions for Use state that leftover medicine after the fourth dose is expected, must not be injected, and must not be transferred to a syringe.
How the published click-count arithmetic is derived
The clinic charts use a convention of 60 clicks for one complete labelled dose. Under that convention, a purely mathematical click count is calculated as:
60 × intended dose ÷ pen’s labelled dose
The table below has been independently recalculated from that formula. It covers the 10, 12.5 and 15 mg pens shown in the supplied educational chart and uses only whole-click results.
| Intended dose | 10 mg pen 0.1667 mg/click* | 12.5 mg pen 0.2083 mg/click* | 15 mg pen 0.25 mg/click* |
|---|---|---|---|
| 2.5 mg | 15 | 12 | 10 |
| 5 mg | 30 | 24 | 20 |
| 7.5 mg | 45 | 36 | 30 |
| 10 mg | 60 | 48 | 40 |
| 12.5 mg | — | 60 | 50 |
| 15 mg | — | — | 60 |
*These per-click figures are mathematical quotients based on 60 clicks per full dose. They are not labelled dose increments, and the device is not calibrated by the Canadian instructions for partial-dose selection. A dash means the intended dose is greater than the pen’s labelled full dose.
Why a mathematically correct table is not the same as a validated dose
Arithmetic can confirm that, for example, 20 is one-third of 60. It cannot establish that every partial rotation delivers a clinically accurate and reproducible volume. The manufacturer’s Canadian instructions validate a complete fixed dose, identified by “1” in the dose window. They do not provide a click-to-milligram table or performance specifications for partial dialling.
Using a pen for more than four weekly injections also changes the labelled handling conditions. The monograph says to discard the KwikPen after four weekly doses and no later than 30 days after first use, even when medicine remains. Residual liquid is intentional and is not a fifth dose. Repeated needle attachment, storage and handling beyond those limits may add sterility, stability and device-performance concerns.
What the source handouts do—and do not—establish
The BC Diabetes handout and the Thames Valley Family Health Team handout are useful examples of how clinicians have explained the calculation and its cost rationale. Both identify click counting as off-label. An international clinic table uses similar arithmetic. None replaces Health Canada-authorized labelling or manufacturer validation for dose accuracy, sterility or stability.
Health Canada’s Drug Product Database record links the marketed Canadian product to its current monograph. When online charts and the labelled instructions differ, the monograph and Instructions for Use should anchor the pharmacist’s counselling.
Practice guidance for pharmacists
- Start with the exact product. Confirm the prescribed milligram dose, the KwikPen strength in hand and whether the patient is using the Canadian multi-dose device.
- Describe the status plainly. Explain that click counting is off-label and that mathematical equivalence does not mean the partial setting has been validated for dose accuracy.
- Do not normalize leftover medicine as an extra dose. Reinforce four fixed weekly doses, disposal after the fourth dose or 30 days after first use, and the instruction not to transfer medicine into a syringe.
- Clarify any intentional off-label plan. If a prescriber has directed partial dosing, obtain explicit written directions, document the discussion and ensure the patient understands the uncertainties and discard date.
- Use teach-back. Ask the patient to explain their dose, pen strength, injection schedule, storage and disposal plan; resolve any mismatch before supply.
- Escalate uncertainty. Contact the prescriber or Lilly medical information when a proposed regimen conflicts with the monograph, cannot be expressed unambiguously or may extend use beyond labelled limits.
